Response of Preterm Infants of Mothers Who Are Chronic Carriers of Both HBsAg and HBeAg to Pre-52 Containing Hepatitis 8 Vaccine (TGP 943) - A Preliminary Report
Abstract
This study aimed to examine the immunogenccity and protective efficacy of a pre-S2 containing hepatitis B vaccine (TGP 943, Takada, Japan) in 9 preterrn infants. A control group of preterm infants were given plasma derived hepatitis B vaccine (Korean Green Cross, Korea). All these preterm infants were born to both HBsAG and HBeAg posistive mothers and born in central General Hospital Sanglah Denpasar from January 3, 1992 to October 30, 1992. The gestational ages were 35-37 weeks and birth weights were 2000-2500 grams. The difference of the anti pre-S2 antibody between two groups of preterm infants was evident at month 6. Anti-HBs antibody response was almost same in the two groups of preterm infants. None in preterm infants in this study became positive for HBsAg during follow-up for at least 6 months. 2 of 8 preterm infants in control group become positive for HBsAg during follow up for a t least 6 months. Our study demonstrated a better anti pre-S2 antibody response and also comparable anti-Hbs antibody response in preterms infants vaccinated with a pre-S2 containing hepatitis B vaccine, compared with those with conventional plasma-derived vaccine.
References
2. Yu LL, Tam AYC, Ng KW< et al. Response of preterm infants to hepatitis B vaccinel. J Pediatr. 1992; 121: 962-5.
3. WHO Report. Meeting of task force on hepatitis B. Regional office for the Western Pacific Manila, Philippines. March, 1984.
4. Kane Mark A, John Clements, Dale Hu. The global control of hepatitis B. In: Assessment and management of risks associated with hepatitis B. Effectiveness of intervention. Philadelphia: Hanley & Belfus; 1990. p.75-92.
5. Hilleman Maurice R. The vaccine solution to the problem of human hepatitis B and it sequelae. In: Assessment and management of risks associated with hepatitis B: Effectiveness of intervention. Philadelphia: Hanley & Belfus, Inc.; 1990. p. 19-31.
6. Neurat AR, Kent SBH, Strick N, Parker A. The biological role of pre-S sequances for vaccine design. Asian Symposisum on Strategies for Large Scale Hipatitis B Immunization. Hongkong; June 12-13, 1986.
7. Adanomicz P, Cuoursaget P, Mazert MC, Goudeaou A, Lagarde D, Girard M. Pre-S antigenity and preS immunogenicity of a hepatitis B vaccine. Asian Symposisum on Strategies for Large Scale Hipatitis B Immunization. Hongkong; June 12-13, 1986.
8. Tiollais P, Michel ML, Millich DR, Chisari FV. Synthesis in chocells of Hepatitis B surface antigen particles containing the pre-S2 region expression product. Asian Symposisum on Strategies for Large Scale Hipatitis B Immunization. Hongkong; June 12-13, 1986.
9. El Goulin. Importance of the production process for the preparation of a safe hepatitis B vaccine of optimal antigenic quality. Asian Symposisum on Strategies for Large Scale Hipatitis B Immunization. Hongkong; June 12-13, 1986.
Copyright (c) 2018 Abdul Hamid Sutohardjo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published 2018-10-08
